Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2017
SIETES contiene 92152 citas

 
 
 1 a 20 de 142 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Anónimo. Drugs for type 2 diabetes. Med Lett Drugs Ther 2017;59:9-18. [Ref.ID 101372]
3. Cita con resumen
Boussageon R, Gueyffier F, Cornu C. Metformin as firstline treatment for type 2 diabetes: are we sure?. BMJ 2016;352:h6748. [Ref.ID 99967]
4. Cita con resumen
Perry TL. Scant evidence on the effectiveness of metformin in type 2 diabetes. BMJ 2015;350:h2650. [Ref.ID 99116]
5. Cita con resumen
Anónimo. HbA1c targets in type 2 diabetes: guidelines and evidence. Drug Ther Bull 2013;51:42-5. [Ref.ID 95196]
6.Enlace a cita original Cita con resumen
Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel J-P, Kassai B, Moreau A, Gueyffier F, Cornu C. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLOS Medicine 2012:abril. [Ref.ID 92585]
7. Cita con resumen
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:1136. [Ref.ID 91918]
8. Cita con resumen
Misra S, Hancock M, Meeran K, Dornhorst A, Oliver NS. HbA1c: an old friend in new clothes. Lancet 2011;377:1476-7. [Ref.ID 90676]
9. Cita con resumen
Pogach L, Aron DC. Sudden accelaration of diabetes quality measures. JAMA 2011;305:709-10. [Ref.ID 90030]
10. Cita con resumen
Roussel R, Travert F, Pasquet B, Wilson PWF, Smith Jr SC, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG, for the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9. [Ref.ID 89701]
11.Enlace a cita original
Bonet Monné S. Dades d'eficàcia dels IECA, ARA II i la combinació d'ambdós grups de fàrmacs. Butlletí d'Informació Terapèutica 2010;22:7-12. [Ref.ID 88270]
12.Enlace a cita original Cita con resumen
Garcia F, Montero Alonso MJ, Merino Senovilla A, Sanz Cantalapiedra R, Maderuelo JA. Las cifras mágicas en la prevención farmacológica de la enfermedad cardiovascular y de fracturas. Boletín de Información Farmacoterapéutica de Navarra 2009;17:49-63. [Ref.ID 87090]
13.Tiene citas relacionadas Cita con resumen
Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72. [Ref.ID 85922]
14.Tiene citas relacionadas
Tamborlane WV, Beck RW. Continuous glucose monitoring in type 1 diabetes mellitus. Lancet 2009;373:1744-6. [Ref.ID 85912]
17. Cita con resumen
Home P. Tight control of blood glucose and cardiovascular disease. BMJ 2008;337:1007-8. [Ref.ID 84400]
18. Cita con resumen
Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL. Cardiovascular outcomes in trials of oral diabetes medications. A systematic review. Arch Intern Med 2008;168:2070-80. [Ref.ID 84324]
19.Tiene citas relacionadas Cita con resumen
Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359:1618-20. [Ref.ID 84164]
20.Tiene citas relacionadas
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year folllow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89. [Ref.ID 84162]
Seleccionar todas
 
 1 a 20 de 142 siguiente >>